Octavus Consulting- Evidence-Based Consulting Services.

Call us: +91 120 428 0707

Email us: bd@octavusconsulting.com

Contact Us
Contact Us

Insights Corner: Highlights from the AACR Annual Meeting 2025

Insights Details

Month: May 25

Tags: AACR, Conference, Pre-clinical, Phase 1, Phase 2, Phase 3, US FDA, EMA, Company Profile, Product profile, Global Market Size, Clinical trials, Landscape, Oncology, Keytruda, Insights

Let’s Work Together for Development

Call us directly, submit a sample or email us!

Business Address
First Floor, B-66, Sector 63,
Noida, UP, India-201301
Connect With Us
Call us: +91 120 428 0707
bd@octavusconsulting.com
Working Hours
Mon - Fri: 10.00 AM - 07.00 PM
Holidays : Closed
Get in Touch With Us

About topic:

AACR 2025 in Chicago brought together over 22,000 participants from 85 countries, underscoring its global reach in cancer research. The meeting featured more than 7,000 sessions, including around 6,200 posters, over 50 major symposia, and six plenary sessions, with a marked year-on-year rise in mini symposia and late-breaking data that highlighted pivotal advances across the cancer research continuum

Insights Corner: Highlights from the AACR Annual Meeting 2025

Highlights:

AACR 2025 highlighted a wave of FIC and next-gen assets, esp. KRAS pathway inhibitors, HER2directed T-cell engagers, AI-designed small molecules, and novel radioligand therapies from players like Novartis and Bayer, signalling where R&D capital is concentrating
Assets such as ABP102/CTP72, AIC100, the Hansoh EGFR TKI, and BriaIMT are positioned as clearly differentiated vs. current benchmarks, often using biomarkers to define responders and to justify premium pricing and better risk–benefit narratives
BriaCell’s BriaIMT/BriaABC vaccine regimen showed improved PFS in select biomarker defined, heavily pretreated metastatic breast cancer subgroups, underscoring the commercial potential of late line, personalized immunotherapies pending confirmatory data
Overall, AACR 2025 emerges as a strong BD and investment venue, with multiple programs explicitly signalling partnering needs and global expansion plans, creating opportunities for pharma BD teams, biotech strategists, and onco-focused investors to secure early access to differentiated pipelines
Get in Touch With Us
PREVIOUS PROJECT
NEXT PROJECT